Evaluation of recombinant Mycoplasma hyopneumoniae P97/P102 paralogs formulated with selected adjuvants as vaccines against mycoplasmal pneumonia in pigs

Vaccine

Volumn 32, Issue 34, 2014, Pages 4333-4341

  Woolley, Lauren K ^a,b   Fell, Shayne A ^a   Gonsalves, Jocelyn R ^a   Raymond, Benjamin B A ^d   Collins, Damian ^a   Kuit, Tracey A ^b   Walker, Mark J ^c   Djordjevic, Steven P ^d   Eamens, Graeme J ^a   Jenkins, Cheryl ^a  

^a NSW DEPARTMENT OF PRIMARY INDUSTRIES   (Australia)

^b UNIVERSITY OF WOLLONGONG   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

Mycoplasma hyopneumoniae; P97 P102 paralogs; Recombinant; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; BACTERIAL VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONTANIDE; RECOMBINANT VACCINE; SUVAXYN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL LOAD; CELL DAMAGE; CELL LYSATE; CELLULAR IMMUNITY; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; COUGHING; CYTOKINE RESPONSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EUKARYOTIC FLAGELLUM; EXPERIMENTAL INFECTION; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOGENICITY; LUNG LESION; MALE; MYCOPLASMA HYOPNEUMONIAE; MYCOPLASMAL PNEUMONIA OF SWINE; NONHUMAN; PARALOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SWINE; TRACHEA MUCOSA; TRACHEOBRONCHIAL LAVAGE FLUID; TRACHEOBRONCHIAL TOILET; VACCINATION; VACCINATION REACTION; WHOLE CELL; ANIMAL; BLOOD; IMMUNOLOGY; LUNG; MICROBIOLOGY; MUCOSAL IMMUNITY; PATHOLOGY; PNEUMONIA OF SWINE, MYCOPLASMAL; TRACHEA;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL LOAD; BACTERIAL VACCINES; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN-1BETA; INTERLEUKIN-6; LUNG; MALE; MYCOPLASMA HYOPNEUMONIAE; PNEUMONIA OF SWINE, MYCOPLASMAL; SWINE; TRACHEA; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, SYNTHETIC;

EID: 84903817947     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.06.008     Document Type: Article

References (49)

1. Thacker E.L. Mycoplasmal diseases. Diseases of swine 2006, 701-717. Blackwell Publishing, Oxford, UK, [chapter 42]. B.E. Straw, J.J. Zimmerman, S. D'Allaire, D. Taylor (Eds.).
2. Thacker E.L., Thacker B.J., Kuhn M., Hawkins P.A., Waters W.R. Evaluation of local and systemic immune responses induced by intramuscular injection of a Mycoplasma hyopneumoniae bacterin to pigs. Am J Vet Res 2000, 61:1384-1389.
3. Seymour L.M., Jenkins C., Deutscher A.T., Raymond B.B.A., Padula M.P., Tacchi J.L., et al. Mhp182 (P102) binds fibronectin and contributes to the recruitment of plasmin(ogen) to the Mycoplasma hyopneumoniae cell surface. J Clin Microbiol 2012, 14:81-94.
4. Jenkins C., Wilton J.L., Minion F.C., Falconer L., Walker M.J., Djordjevic S.P. Two domains within the Mycoplasma hyopneumoniae cilium adhesin bind heparin. Infect Immun 2006, 74:481-487.
5. Wilton J., Jenkins C., Cordwell S.J., Falconer L., Minion F.C., Oneal D.C., et al. Mhp493 (P216) is a proteolytically processed, cilium and heparin binding protein of Mycoplasma hyopneumoniae. Mol Microbiol 2006, 71:566-582.
6. Burnett T.A., Dinkla K., Rohde M., Chhatwal G.S., Uphoff C., Srivastava M., et al. P159 is a proteolytically processed, surface adhesin of Mycoplasma hyopneumoniae: defined domains of P159 bind heparin and promote adherence to eukaryote cells. Mol Microbiol 2006, 60:669-686.
7. Bogema D.R., Scott N.E., Padula M.P., Tacchi J.L., Raymond B.B.A., Jenkins C., et al. Sequence TTKF (down arrow) QE defines the site of proteolytic cleavage in Mhp683 protein, a novel glycosaminoglycan and cilium adhesin of Mycoplasma hyopneumoniae. J Biol Chem 2011, 286:41217-41229.
8. Bogema D.R., Deutscher A.T., Woolley L.K., Seymour L.M., Raymond B.B.A., Tacchi J.L., et al. Characterisation of cleavage events in the multifunctional cilium adhesin Mhp684 (P146) reveals a mechanism by which Mycoplasma hyopneumoniae regulates surface topography. mBio 2012, 3:1-11.
9. Seymour L.M., Deutscher A.T., Jenkins C., Kuit T.A., Falconer L., Minion F.C., et al. A processed multi-domain Mycoplasma hyopneumoniae adhesin binds fibronectin, plasminogen and swine respiratory cilia. J Biol Chem 2010, 285:33971-33978.
10. Seymour L.M., Falconer L., Deutscher A.T., Minion F.C., Padula M.P., Dixon N.E., et al. Mhp107 is a member of the multifunctional adhesin family of Mycoplasma hyopneumoniae. J Biol Chem 2011, 286:10097-10104.
11. Deutscher A.T., Jenkins C., Minion F.C., Seymour L.M., Padula M.P., Dixon N.E., et al. Repeat regions R1 and R2 in the P97 paralogue Mhp271 of Mycoplasma hyopneumoniae bind heparin, fibronectin and porcine cilia. Mol Microbiol 2010, 78:444-458.
12. Deutscher A.T., Tacchi J.L., Minion F.C., Padula M.P., Crossett B., Bogema D.R., et al. Mycoplasma hyopneumoniae surface proteins Mhp385 and Mhp384 bind host cilia and glycosaminoglycans and are endoproteolytically processed by proteases that recognise different cleavage motifs. J Proteome Res 2012, 11:1924-1936.
13. Zhang Q., Young T.F., Ross R.F., Zhang Q.J. Identification and characterisation of a Mycoplasma hyopneumoniae adhesin. Infect Immun 1995, 63:1013-1019.
14. Chen J.R., Liao C.W., Mao S.J., Weng C.N. A recombinant chimera composed of repeat region RR1 of Mycoplasma hyopneumoniae adhesion with Pseudomonas exotoxin: in vivo evaluation of specific IgG response in mice and pigs. Vet Microbiol 2001, 80:297-357.
15. Conceicao F.R., Moreira A.N., Dellagostin O.A. A recombinant chimera composed of R1 repeat region of Mycoplasma hyopneumoniae P97 adhesin with Escherichia coli heat-liable enterotoxin B subunit elicits immune response in mice. Vaccine 2006, 24:5729-5743.
16. King K.W., Faulds D.H., Rosey E.L., Yancey R.J. Characterisation of the gene encoding Mhp1 from Mycoplasma hyopneumoniae and examination of Mhp1's vaccine potential. Vaccine 1997, 15:25-35.
17. Woolley L.K., Fell S., Gonsalves J.R., Walker M.J., Djordjevic S.P., Jenkins C., et al. Evaluation of clinical, histological and immunological changes and qPCR detection of Mycoplasma hyopneumoniae in tissues during the early stages of mycoplasmal pneumonia in pigs after experimental challenge with two field isolates. Vet Microbiol 2012, 161:186-195.
18. Woolley L.K., Fell S.A., Djordjevic S.P., Eamens G.J., Jenkins C. Plasmin activity in the porcine airways is enhanced during experimental infection with Mycoplasma hyopneumoniae, is positively correlated with proinflammatory cytokine levels and is ameliorated by vaccination. Vet Microbiol 2013, 164:60-66.
19. Choi C., Kwon D., Jung K., Ha Y., Lee Y.H., Kim O., et al. Expression of inflammatory cytokines in pigs experimentally infected with Mycoplasma hyopneumoniae. J Comp Pathol 2006, 129:40-46.
20. Lorenzo H., Quesada O., Assuncao P., Castro A., Rodriguez F. Cytokine expression in porcine lungs experimentally infected with Mycoplasma hyopneumoniae. Vet Immunol Immunopathol 2006, 109:199-207.
21. Rodriguez F., Ramirez G.A., Sarradell J., Andrada M., Lorenzo H. Immunohistochemical labelling of cytokines in lung lesions of pigs naturally infected with Mycoplasma hyopneumoniae. J Comp Pathol 2004, 130:306-312.
22. Naim J.O., van Oss C.J., Wu W., Giese R.F., Nickerson P.A. Mechanisms of adjuvancy: I - Metal oxides as adjuvants. Vaccine 1997, 15:1183-1193.
23. Brewer J.M., Conacher M., Hunter C.A., Mohrs M., Brombacher R., Alexander J. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4 or IL-13-mediated signalling. J Immunol 1999, 163:6448-6454.
24. Edelman R. The development and use of vaccine adjuvants. Mol Biotechnol 2002, 21:129-148.
25. Montanide™ Gel safety and efficacy profile update. Seppic Technical Bulletin 2008, SEPPIC, Paris.
26. Scarman A.L., Chin J.C., Eamens G.J., Delaney S.F., Djordjevic S.P. Identification of novel species-specific antigens of Mycoplasma hyopneumoniae by preparative SDS-PAGE ELISA profiling. Microbiology 1997, 143:663-673.
27. Sambrook J., Fritsch E.F., Maniatis T. Molecular cloning: a laboratory manual 1989, Cold Spring Harbor, New York. 2nd ed.
28. Freundt E.A., Erno H. Identification of mycoplasmas. Methods in microbiology 1979, p407. Academic Press, London. T. Bergan, J.R. Norris (Eds.).
29. Eamens G.J., Gonsalves J.R., Whittington A.M., Turner B. Serological responses to two serovar-independent ELISA antigens of Actinobacillus pleuropneumoniae in Australian commercial pig herds. Aust Vet J 2008, 86:465-472.
30. Goodwin R.F.W., Hodgson R.G., Whittlestone P., Woodhams R.L. Some experiments relating to artificial immunity in enzootic pneumonia of pigs. J Hyg Cambr 1969, 67:465-476.
31. Strait E.L., Madsen M.L., Minion F.C., Christopher-Hennings J., Dammen M., Jones K.R., et al. Real-time PCR assays to address genetic diversity among strains of Mycoplasma hyopneumoniae. J Clin Microbiol 2008, 46:2491-2498.
32. Marchioro S.B., Maes D., Flahou B., Pasmans F., Sacristan R.D.P., Vranckx K., et al. Local and systemic immune responses in pigs intramuscularly injected with an inactivated Mycoplasma hyopneumoniae vaccine. Vaccine 2013, 31:1305-1311.
33. Young T.F., Chiang Y.-W., Ross R.F. Evaluation of local and systemic humoral immune responses to Mycoplasma hyopneumoniae. Proceedings of the 11th congress of the International Pig Veterinary Society 1990, 97.
34. Djordjevic S.P., Cordwell S.J., Djordjevic M.A., Wilton J.L., Minion F.C. Proteolytic processing of the Mycoplasma hyopneumoniae cilium adhesin. Infect Immun 2004, 72:2791-2802.
35. Lui W., Xiao S., Li M., Guo S., Li S., Luo R., et al. Comparative genomic analyses of Mycoplasma hyopneumoniae pathogenic 168 strain and its high-passaged attenuated strain. BMC Genomics 2013, 14:80.
36. Calus D., Baele M., Meyns T., de Kruif A., Butaye P., Decostere A., et al. Protein variability among Mycoplasma hyopneumoniae isolates. Vet Microbiol 2007, 120:284-291.
37. Thacker E.L., Thacker B.J., Boettcher T.B., Jayappa H. Comparison of antibody production, lymphocyte stimulation, and protection induced by four commercial Mycoplasma hyopneumoniae bacterins. Swine Health Prod 1998, 6:107-112.
38. Djordjevic S.P., Eamens G.J., Romalis L.F., Nicholls P.J., Taylor V., Chin J. Serum and mucosal antibody responses and protection in pigs vaccinated against Mycoplasma hyopneumoniae with vaccines containing a denatured membrane antigen pool and adjuvant. Aust Vet J 1997, 75:504-511.
39. Davenport M.P., Grimm M.C., Lloyd A.R. A homing selection hypothesis for T-cell trafficking. Immunol Today 2000, 21:315-317.
40. Hausner M., Schamberger A., Naumann W., Jacobs E., Dumke R. Development of protective anti-Mycoplasma pneumoniae antibodies after immunisation of guinea pigs with the combination of a P1-P30 chimeric recombinant protein. Microb Pathog 2013, 64:23-32.
41. Ralli-Jain P., Tifrea D., Cheng C., Pal S., de la Maza L.M. Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunisation. Vaccine 2010, 28:7659-7666.
42. Crouch C.F., Daly J., Henley W., Hannant D., Wilkins J., Francis M.J. The use of a systemic prime/mucosal boost strategy with an equine influenza ISCOM vaccine to induce protective immunity in horses. Vet Immunol Immunopathol 2005, 108:345-355.
43. Ogawa Y., Oishi E., Muneta Y., Sano A., Hikono H., Shibahara T., et al. Oral vaccination against mycoplasmal pneumonia of swine using Erysipelothrix rhusiopathiae vaccine strain as a vector. Vaccine 2009, 27:4543-4550.
44. Okamba F.R., Arella M., Music N., Jia J.J., Gottschalk M., Gagnon C.A. Potential use of a recombinant replication-defective adenovirus vector carrying the C-terminal portion of the P97 adhesin protein as a vaccine against Mycoplasma hyopneumoniae in swine. Vaccine 2010, 28:4802-4809.
45. Marois C., Dory D., Fablet C., Madec F., Kobisch M. Development of a quantitative Real-Time TaqMan PCR assay for determination of the minimal dose of Mycoplasma hyopneumoniae strain 116 required to induce pneumonia in SPF pigs. J Appl Microbiol 2010, 108:1523-1533.
46. Burysek L., Syrovets T., Simmet T. The serine protease plasmin triggers expression of MCP-1 and CD40 in human primary monocytes via activation of p38 MAPK and janus kinase (JAK)/STAT signalling pathways. J Biol Chem 2002, 277:33509-33517.
47. Syrovets T., Jendrach M., Rohwedder A., Schule A., Simmet T. Plasmin-induced expression of cytokines and tissue factor in human monocytes involves AP-1 and IKKbeta-mediated NF-kappaB activation. Blood 2001, 97:3941-3950.
48. Kucharewicz I., Kowal K., Buczko W., Bodzenta-Lukaszyk A. The plasmin system in airway remodelling. Thromb Res 2003, 112:1-7.
49. Li Q., Laumonnier Y., Syrovets T., Simmet T. Plasmin triggers cytokine induction in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol 2007, 27:1383-1389.